Welcome to our dedicated page for BED BATH & BEYOND SEC filings (Ticker: BBBY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bed Bath & Beyond, Inc. filings document an ecommerce-focused retailer’s operating results, material agreements, acquisition activity, governance matters, and capital structure. Form 8-K reports include quarterly and annual financial-result releases, material definitive agreements, completion reports for acquisitions such as The Brand House Collective, executive appointments, compensation arrangements, and other corporate events.
Proxy and registration-related filings cover annual meeting proposals, director elections, auditor ratification, say-on-pay matters, charter amendments, equity-plan matters, shareholder voting mechanics, and disclosures tied to common stock and warrants. The filing record also addresses the company’s brand portfolio, retail execution, technology and administrative costs, risk factors, and public-company governance.
Bed Bath & Beyond, Inc. announced leadership changes focused on finance and board governance. The Board appointed Chief Financial Officer Brian LaRose to also serve as principal accounting officer, effective May 15, 2026, replacing Leah Putnam in that role. The company states there are no special arrangements behind his appointment and notes that he has no family ties or related-party transactions with directors or executives that require disclosure.
The Board also appointed Tamara Ward as a director effective May 15, 2026, with her term running until the 2027 annual stockholder meeting or earlier departure. She was named Chair of the Compensation Committee and a member of the Audit Committee. Under the existing non-employee director compensation program, Ward received restricted stock units valued at $165,000 and will earn a $75,000 annual cash retainer, paid quarterly. The company plans to enter into its standard indemnification agreement with her and reports no related-party transactions requiring disclosure.
BED BATH & BEYOND, INC. director Tamara Ward reported a compensation-related equity grant. She received 36,105 restricted stock units, each representing a contingent right to receive one share of common stock. These restricted stock units vest at the close of business on May 14, 2027, with vested shares delivered promptly after vesting.
Following this grant, Ward beneficially owns 36,105 restricted stock units from the reported award, all held as a direct interest. This is not an open‑market purchase or sale but a grant, award, or other acquisition as part of her role with the company.
BED BATH & BEYOND, INC. director Tamara Ward filed an initial insider ownership report on Form 3. This filing establishes her status as a reporting person and does not list any share purchases, sales, or other transactions at this time.
Bed Bath & Beyond reports results of its 2026 annual meeting. Stockholders approved a Charter amendment doubling authorized common shares from 100,000,000 to 200,000,000, giving the company more flexibility to issue stock in the future.
They also approved an amendment and restatement of the 2005 Equity Incentive Plan, adding 4,291,000 newly authorized shares for employee equity awards, plus additional shares through updated recycling provisions. All director nominees were elected, KPMG LLP was ratified as auditor for 2026, executive compensation received advisory approval, and an adjournment proposal passed but was not used. The meeting had a quorum with 49,326,700 of 69,342,333 eligible shares represented.
Bed Bath & Beyond’s former Chief Accounting Officer Leah R. Putnam reported multiple equity compensation events in the company’s common stock. On May 14, 2026, she exercised performance shares and restricted stock units into a total of 75,013 shares of common stock, while 18,268 shares were disposed of at $4.69 per share to cover tax liabilities. She also received a grant of 1,068 restricted stock units, which were approved by shareholders on May 14, 2026. Footnotes state that several restricted stock units and performance shares had their vesting accelerated in connection with her departure from the company, with vested shares to be delivered promptly after vesting.
Bed Bath & Beyond director Barclay Corbus reported several equity compensation moves. On May 15, 2026, he exercised 26,873 restricted stock units into common shares, bringing his direct common stock holdings to 105,047 shares.
He also received a new grant of 35,181 restricted stock units on May 14, 2026, which will vest at the close of business on May 14, 2027. In addition, he holds 7,816 common stock warrants originally issued on October 7, 2025, each allowing purchase of one common share at an exercise price of $15.50 per warrant through October 7, 2026.
Bed Bath & Beyond director William Benjamin Nettles Jr. reported compensation-related equity transactions, with no open-market buying or selling. On May 15, 2026, restricted stock units covering 26,873 shares of common stock vested and were delivered, increasing his direct common stock holdings to 49,747 shares.
On May 14, 2026, he received a new grant of 35,181 restricted stock units, each representing a contingent right to one share of common stock that vests at the close of business on May 14, 2027. The filing also notes 2,286 common stock warrants originally issued on October 7, 2025 as a pro‑rata distribution to all common shareholders, each with a $15.50 exercise price.
Bed Bath & Beyond director Robert Jacob Shapiro increased his equity stake through compensation-related stock transactions. On May 15, 2026, 26,873 restricted stock units vested and were converted into the same number of common shares at no cost, bringing his direct common stock holdings to 67,107 shares.
On May 14, 2026, he received a new award of 35,181 restricted stock units, each representing a right to one future common share that vests on May 14, 2027. He also holds 4,022 common stock warrants, each allowing the purchase of one share at an exercise price of $15.50 per share, originally distributed pro rata to all common stockholders in October 2025.
Bed Bath & Beyond director Joanna M. Burkey reported compensation-related equity activity. On May 15, 2026, 26,873 restricted stock units vested and were delivered as common shares, bringing her directly held common stock to 42,417 shares. The day before, she received a new grant of 35,181 restricted stock units that vest on May 14, 2027. She also holds 1,554 common stock warrants, each exercisable for one share at an exercise price of $15.50, from a pro-rata distribution originally issued on October 7, 2025.
Bed Bath & Beyond director Debra Golding Perelman reported equity compensation activity, acquiring shares through RSU vesting and receiving new awards. On May 15, 2026, 26,873 restricted stock units converted into the same number of common shares at a price of $0.00, increasing her direct common stock holdings to 32,174 shares.
On May 14, 2026, she received a grant of 35,181 restricted stock units, each representing a contingent right to one common share that vests at the close of business on May 14, 2027. She also holds 530 common stock warrants that were originally issued on October 7, 2025 in a pro-rata distribution to all common shareholders, each exercisable for one common share at an exercise price of $15.50 per warrant until October 7, 2026.